Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
The approval was based on findings from the phase III, global, head-to-head HAWK and HARRIER studies, wherein Beovu demonstrated non-inferiority to Regeneron/Bayer’s market-leading drug, Eylea (aflibercept), in mean change in best-corrected visual acuity from baseline to year one. Pfizer’s Vyndaqel Gets Approved in Europe: The EC also granted approval to Pfizer’s Vyndaqel (tafamidis) capsule (61 mg) to treat wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM), a rare and fatal illness associated with progressive heart failure. Sanofi, J&J Sign Deal With BARDA for Coronavirus Vaccine: Sanofi signed a deal with with BARDA to quickly advance development of a vaccine for COVID-19, the disease caused by the novel coronavirus, also called 2019-nCoV. Earlier this month, J&J had said that BARDA will share the R&D costs and provide funds to rapidly advance its COVID-19 vaccine development program into phase I clinical studies.